Opportunities / DEPT OF DEFENSE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

Description (excerpt)

This is a continuous, open announcement with no deadline unless specifically noted. (Please note this posting was formerly the Threat Agnostic Host-Directed Therapeutics/HEALER PBA. If a white paper was previously submitted under the HEALER name, then the submission is still valid for the revised annoucement.) Issuing Organization Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) 1. Strategic Opportunity The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) invites interested parties to enter into the CBRN Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. To maximize the efficacy of the advanced MCMs detailed in this agreement, the CPE CBRND recognizes that therapeutic intervention is intrinsically linked to rapid, and effective patient diagnosis. Consequently, this PBA includes an integrated focus on diagnostics. This PBA establishes a unified, open, and continuous network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation CBRN medical defense solutions. The goal is to create a streamlined framework for awarding follow-on project agreements, fostering a long-term, collaborative relationship with the Government. 2. Program Vision: Building Holistic Threat Resilience The overarching goal of the CBRN MCM PBA is to develop and field a comprehensive suite of MCMs, inclusive of medical devices, drugs and biologics, to protect the warfighter within a complex and evolving CBRN threat space. This PBA is designed as an agile agreement supporting a wide range of acquisition strategies and technologies, from rapid prototyping to late-stage development and FDA licensure or clearance. To build an integrated layered defense, the Government seeks innovative solutions across the continuum of care. This includes both pathogen or agent-based and host-based diagnostics, treatments, pre-exposure or post-exposure prophylactic countermeasures, as well as ruggedized formulations, novel drug delivery systems, and adaptable platform technologies capable of rapidly pivoting to address new and emerging threats. This integrated approach will ensure the development of a diverse and robust portfolio of MCM capabilities, preserving the Joint Force through enhanced resilience. Examples of capabilities sought under this PBA include, but are not limited to: Host-Targeted Resilience: Development efforts focus on providin …

View the official notice on SAM.gov →